<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-23843" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Kaposi Varicelliform Eruption</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Karray</surname>
            <given-names>Mehdi</given-names>
          </name>
          <aff>Rabta Hospital</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Kwan</surname>
            <given-names>Eddie</given-names>
          </name>
          <aff>Uniformed Services University of the Health Sciences</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Souissi</surname>
            <given-names>Asmahen</given-names>
          </name>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Mehdi Karray declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Eddie Kwan declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Asmahen Souissi declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>12</day>
          <month>9</month>
          <year>2022</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-23843.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Kaposi varicelliform eruption, also known as eczema herpeticum, is a disseminated viral skin infection that typically affects individuals with underlying skin conditions such as atopic dermatitis. Herpes simplex virus is the primary cause, but other skin conditions like pemphigus foliaceus, bullous pemphigoid, and psoriasis may also be associated with the eruption. Clinically, the condition presents as widespread clusters of umbilicated vesicles and pustules that evolve into crusted skin erosions, with the trunk, neck, and head being most commonly affected. Timely antiviral therapy is crucial, as the condition is potentially life-threatening if not promptly treated.</p>
        <p>Participants in this course learn to recognize the clinical features of Kaposi varicelliform eruption, evaluate the need for diagnostic tests such as Tzanck smears or viral cultures, and implement early antiviral treatment to reduce complications. The course highlights the importance of interprofessional collaboration, particularly between dermatologists, infectious disease specialists, and nursing staff, to ensure prompt diagnosis and coordinated care, ultimately improving patient outcomes and reducing morbidity.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the clinical signs and symptoms of Kaposi varicelliform eruption to ensure prompt diagnosis.</p></list-item><list-item><p>Differentiate Kaposi varicelliform eruption from other vesicular skin infections or dermatological conditions.</p></list-item><list-item><p>Screen patients with underlying skin diseases, such as atopic dermatitis, for early signs of viral dissemination.</p></list-item><list-item><p>Communicate&#x000a0;the importance of interprofessional communication and collaboration when evaluating and managing cases of Kaposi varicelliform eruptions.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=23843&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=23843">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-23843.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Kaposi varicelliform eruption, also called eczema herpeticum, refers to a disseminated skin infection due to a virus that usually leads to localized vesicular eruptions in a patient with an underlying cutaneous disease. Although rare, it is a potentially life-threatening disorder. Herpes simplex virus is considered the main causative agent.<xref ref-type="bibr" rid="article-23843.r1">[1]</xref><xref ref-type="bibr" rid="article-23843.r2">[2]</xref><xref ref-type="bibr" rid="article-23843.r3">[3]</xref>&#x000a0;The most commonly reported cases occur in patients with atopic dermatitis. However, it has been described in association with other skin conditions such as pemphigus foliaceus, ichthyosis vulgaris, bullous pemphigoid, Darier disease, Grover disease, Hailey-Hailey disease, dyskeratosis follicularis, mycosis&#x000a0;fungoides, Sezary syndrome, psoriasis, pityriasis rubra pilaris, rosacea, seborrheic dermatitis, contact dermatitis (both allergic and irritant),&#x000a0;second-degree burns and&#x000a0;skin grafts.<xref ref-type="bibr" rid="article-23843.r4">[4]</xref> Clinical features of Kaposi varicelliform eruption include widespread clusters of umbilicated vesicles and pustules that evolve into crusted skin erosions (See<bold> Image.&#x000a0;</bold>Kaposi&#x000a0;Varicelliform&#x000a0;Eruption).</p>
        <list list-type="bullet">
          <list-item>
            <p>The most frequently affected sites are the trunk, neck, and head.</p>
          </list-item>
          <list-item>
            <p>The diagnosis of Kaposi varicelliform eruption is made primarily on clinical findings.</p>
          </list-item>
          <list-item>
            <p>The Tzanck smear, viral cultures, skin biopsy, or detection of viral deoxyribonucleic acid by polymerase chain reaction may be helpful in doubtful cases.</p>
          </list-item>
          <list-item>
            <p>Antiviral therapy has been effective but should be started as soon as possible after diagnosis to reduce morbidity and mortality.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-23843.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Kaposi varicelliform eruption is caused mainly by herpes simplex virus type 1;&#x000a0;however, other viral agents such as herpes simplex virus type 2, Coxsackie A16, vaccinia, varicella zoster, and smallpox&#x000a0;also&#x000a0;have been involved in its pathogenesis.</p>
      </sec>
      <sec id="article-23843.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Kaposi varicelliform eruption is a rare condition first described in 1887 by&#x000a0;Moritz Kaposi. This condition occurs more frequently in children due to its relationship with atopic dermatitis; however, adult cases have been reported. The incidence is not precisely known due to its rarity and the lack of a large case series.<xref ref-type="bibr" rid="article-23843.r5">[5]</xref><xref ref-type="bibr" rid="article-23843.r6">[6]</xref>&#x000a0;The disease equally affects men and women and does not appear to have a specific ethnic predominance.</p>
      </sec>
      <sec id="article-23843.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>Kaposi varicelliform eruption&#x000a0;was initially&#x000a0;assumed to be secondary to a fungal infection. However, the finding of cytoplasmic inclusion bodies in the histological examination suggested a viral origin. The mechanisms underlying the pathogenesis of viral reactivation in Kaposi varicelliform eruption remain incompletely understood. There is a belief that a defective skin barrier acting in conjunction&#x000a0;with immune deficiencies seems to lead to the development of the disease. Both cell-mediated and humoral immunity dysfunction are implicated; in addition, the Th2 cytokine environment found in atopic dermatitis seems crucial.<xref ref-type="bibr" rid="article-23843.r7">[7]</xref>&#x000a0;Results from many recent studies suggest&#x000a0;a genetic contribution to the pathogenesis of Kaposi varicelliform eruption.</p>
      </sec>
      <sec id="article-23843.s6" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>A skin biopsy is not required to confirm a diagnosis, but if it is performed, histological findings include intra-epidermal blister, acantholysis, multinuclear giant cells with intranuclear inclusion, and ballooning degeneration of the keratinocytes.</p>
      </sec>
      <sec id="article-23843.s7" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Patients with Kaposi varicelliform eruption present with a sudden skin eruption of painful clusters of umbilicated vesicles and pustules. Vesiculopustules often evolve into crusted, hemorrhagic, and punched-out skin erosions that may enlarge and coalesce to form extensive denuded areas more likely to get a bacterial infection. The distribution of affected skin reflects the crucial role of skin barrier impairment since Kaposi varicelliform eruption begins in areas of underlying dermatosis. This inaugural topographic distribution may lead to a delayed diagnosis because the eruption is often confused with the pre-existing condition. Kaposi varicelliform eruption may be associated with systemic symptoms such as malaise, high temperature, and swollen lymph nodes. In addition, the disease can be complicated by multiple organ involvements, mainly of the central nervous system, liver, lungs, gastrointestinal tract, and adrenal glands.</p>
      </sec>
      <sec id="article-23843.s8" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>The diagnosis of Kaposi varicelliform eruption is mainly based on a clinical examination, although several laboratory tests can be helpful.<xref ref-type="bibr" rid="article-23843.r8">[8]</xref><xref ref-type="bibr" rid="article-23843.r9">[9]</xref>&#x000a0;A Tzanck smear is performed by scraping the floor of an opened vesicle and staining the material with Wright-Giemsa stain, demonstrating&#x000a0;multinucleated giant cells. The test is inexpensive, easily applicable, and quick to perform. However, this method suffers from low sensitivity and does not differentiate between herpes simplex virus 1 and 2 or between herpes simplex virus and varicella-zoster virus.</p>
        <p>Viral culture and direct fluorescence antibody staining on Tzanck smear are the most reliable techniques for herpes simplex virus detection. A skin biopsy or polymerase chain reaction may be performed in case of atypical, equivocal, or old lesions. A histological examination may confirm a diagnosis that may not have been thought of clinically, whereas polymerase chain reaction detects viral deoxyribonucleic acid by polymerase chain reaction.</p>
      </sec>
      <sec id="article-23843.s9" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Treatment of Kaposi varicelliform eruption must be instituted with no delay since it is a potentially life-threatening disease. Antiviral therapy is effective in reducing morbidity and preventing complications. Nucleoside analogs are the antiviral agents most commonly used since they inhibit viral deoxyribonucleic acid replication.<xref ref-type="bibr" rid="article-23843.r10">[10]</xref><xref ref-type="bibr" rid="article-23843.r11">[11]</xref><xref ref-type="bibr" rid="article-23843.r12">[12]</xref></p>
        <p>Acyclovir is the most widely studied and prescribed drug for Kaposi varicelliform eruption. High-dose intravenous acyclovir is often necessary for disease control. Most patients achieve resolution of the skin lesions over several days. Prophylactic treatment with systemic antibiotics is recommended to prevent secondary bacterial infection.</p>
      </sec>
      <sec id="article-23843.s10" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>Kaposi varicelliform eruption may be confused with various conditions:</p>
        <list list-type="bullet">
          <list-item>
            <p>Chickenpox</p>
          </list-item>
          <list-item>
            <p>Impetigo</p>
          </list-item>
          <list-item>
            <p>Allergic contact dermatitis</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-23843.s11" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>Kaposi varicelliform eruption is a serious condition that may have fatal outcomes. The disease may occur as a primary or a recurrent type of&#x000a0;infection. The primary form mainly concerns children and is usually disseminated and associated with systemic symptoms and life-threatening complications such as bacterial sepsis, viremia,&#x000a0;and multiple organ involvement. The recurrent type occurs in adulthood and is usually a milder and more localized form, generally presenting without viremia.</p>
        <p>Septicemia resulting from secondary bacterial infection of cutaneous lesions also increases morbidity and mortality. The most common species isolated from patients with Kaposi varicelliform eruption are <italic toggle="yes">Staphylococcus aureus</italic>, group A<italic toggle="yes"> beta-hemolytic streptococcus</italic>, <italic toggle="yes">Peptostreptococcus</italic>, and <italic toggle="yes">Pseudomonas aeruginosa</italic>. A risk of ocular involvement exists when herpes simplex virus-associated Kaposi varicelliform eruption affects the face. Ocular anomalies include uveitis, conjunctivitis, keratitis, and blepharitis. The most serious ophthalmological sequela is herpetic keratitis, which may lead to vision loss resulting from corneal scarring.</p>
      </sec>
      <sec id="article-23843.s12" sec-type="Pearls and Other Issues">
        <title>Pearls and Other Issues</title>
        <p>Kaposi varicelliform eruption should be diagnosed accurately since it may have fulminant outcomes. Although there is no consensual therapeutic approach, the early use of antiviral therapy associated with systemic antibiotics is crucial.</p>
      </sec>
      <sec id="article-23843.s13" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Kaposi varicelliform eruption may present to&#x000a0;any interprofessional team member; the most important thing is to refer these patients immediately to the dermatologist. The diagnosis is clinical, but the general practitioner may not have the clinical expertise to make this diagnosis. If the eye is affected, an ophthalmology consult should be made</p>
        <p>Treatment of Kaposi varicelliform eruption must be instituted with no delay since it is a potentially life-threatening disease. Antiviral therapy is effective in reducing morbidity and preventing complications.&#x000a0;Acyclovir is the most widely studied and prescribed drug for Kaposi varicelliform eruption. High-dose intravenous acyclovir is often necessary for disease control, so a pharmacist should be involved to verify dosing and perform medication reconciliation. Most patients achieve resolution of the skin lesions over several days. Prophylactic treatment with systemic antibiotics is recommended to prevent secondary bacterial infection.&#x000a0;Clinicians&#x000a0;administer these drugs and need to be aware of the signs of adverse drug reactions, as well as monitor the progress of treatment. These patients need close monitoring until the lesions have resolved, and management by an interprofessional team is the optimal approach.<xref ref-type="bibr" rid="article-23843.r13">[13]</xref></p>
      </sec>
      <sec id="article-23843.s14">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=23843&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=23843">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/skin-problems-and-treatments/kaposi-varicelliform-eruption/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=23843">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/23843/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=23843">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-23843.s15">
        <fig id="article-23843.image.f1" position="float" orientation="portrait">
          <caption>
            <p>Kaposi Varicelliform Eruption. Kaposi varicelliform eruption, also called eczema herpeticum, refers to a disseminated skin infection due to a virus that usually leads to localized vesicular eruptions that occur in a patient with an underlying cutaneous disease.&#x000a0;Although rare, it is a potentially life-threatening disorder. Herpes simplex virus is considered the primary causative agent. Contributed by&#x000a0;O Chaigasame</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Kapsosi__Varicelliform" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-23843.s16">
        <title>References</title>
        <ref id="article-23843.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Skrek</surname>
                <given-names>SV</given-names>
              </name>
              <name>
                <surname>Timoshchuk</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Sidikov</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Zaslavsky</surname>
                <given-names>DV</given-names>
              </name>
              <name>
                <surname>Megna</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Kaposi varicelliform eruption induced by methotrexate in an adult atopic dermatitis patient.</article-title>
            <source>Dermatol Ther</source>
            <year>2019</year>
            <month>Mar</month>
            <volume>32</volume>
            <issue>2</issue>
            <fpage>e12826</fpage>
            <pub-id pub-id-type="pmid">30659717</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23843.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Miller</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Trowbridge</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Desai</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Drews</surname>
                <given-names>RE</given-names>
              </name>
            </person-group>
            <article-title>Kaposi's varicelliform eruption in a patient with metastatic melanoma and primary cutaneous anaplastic large cell lymphoma treated with talimogene laherparepvec and nivolumab.</article-title>
            <source>J Immunother Cancer</source>
            <year>2018</year>
            <month>Nov</month>
            <day>19</day>
            <volume>6</volume>
            <issue>1</issue>
            <fpage>122</fpage>
            <pub-id pub-id-type="pmid">30454071</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23843.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gottesman</surname>
                <given-names>SP</given-names>
              </name>
              <name>
                <surname>Rosen</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Geller</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Freeman</surname>
                <given-names>BB</given-names>
              </name>
            </person-group>
            <article-title>Atypical Varicella-Zoster Kaposi Varicelliform Eruption in S&#x000e9;zary Syndrome.</article-title>
            <source>Am J Dermatopathol</source>
            <year>2018</year>
            <month>Dec</month>
            <volume>40</volume>
            <issue>12</issue>
            <fpage>920</fpage>
            <page-range>920-923</page-range>
            <pub-id pub-id-type="pmid">30211729</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23843.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Azmi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Nasim</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Dodani</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Laiq</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Mehdi</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Mubarak</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Kaposi Varicelliform Eruption Associated With Chickenpox in a Liver Transplant Recipient.</article-title>
            <source>Exp Clin Transplant</source>
            <year>2020</year>
            <month>Apr</month>
            <volume>18</volume>
            <issue>2</issue>
            <fpage>252</fpage>
            <page-range>252-254</page-range>
            <pub-id pub-id-type="pmid">29957162</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23843.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gruhl</surname>
                <given-names>RR</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Niermann</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Olson</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Not all that vesicles is herpes.</article-title>
            <source>Diagnosis (Berl)</source>
            <year>2017</year>
            <month>Nov</month>
            <day>27</day>
            <volume>4</volume>
            <issue>4</issue>
            <fpage>261</fpage>
            <page-range>261-264</page-range>
            <pub-id pub-id-type="pmid">29536938</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23843.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Okamoto</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Takahagi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Tanaka</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ogawa</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Nobuki</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Hide</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>A case of Kaposi varicelliform eruption progressing to herpes simplex virus hepatitis in an immunocompetent patient.</article-title>
            <source>Clin Exp Dermatol</source>
            <year>2018</year>
            <month>Jul</month>
            <volume>43</volume>
            <issue>5</issue>
            <fpage>636</fpage>
            <page-range>636-638</page-range>
            <pub-id pub-id-type="pmid">29446473</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23843.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sato</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Hiromatsu</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Murata</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Imafuku</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Loss of ATP2A2 Allows Herpes Simplex Virus 1 Infection of a Human Epidermis Model by Disrupting Innate Immunity and&#x000a0;Barrier Function.</article-title>
            <source>J Invest Dermatol</source>
            <year>2018</year>
            <month>Dec</month>
            <volume>138</volume>
            <issue>12</issue>
            <fpage>2540</fpage>
            <page-range>2540-2549</page-range>
            <pub-id pub-id-type="pmid">29870688</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23843.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sun</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Ong</surname>
                <given-names>PY</given-names>
              </name>
            </person-group>
            <article-title>Infectious Complications in Atopic Dermatitis.</article-title>
            <source>Immunol Allergy Clin North Am</source>
            <year>2017</year>
            <month>Feb</month>
            <volume>37</volume>
            <issue>1</issue>
            <fpage>75</fpage>
            <page-range>75-93</page-range>
            <pub-id pub-id-type="pmid">27886912</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23843.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lehman</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>el-Azhary</surname>
                <given-names>RA</given-names>
              </name>
            </person-group>
            <article-title>Kaposi varicelliform eruption in patients with autoimmune bullous dermatoses.</article-title>
            <source>Int J Dermatol</source>
            <year>2016</year>
            <month>Mar</month>
            <volume>55</volume>
            <issue>3</issue>
            <fpage>e136</fpage>
            <page-range>e136-40</page-range>
            <pub-id pub-id-type="pmid">26500144</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23843.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lyons</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Milner</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Stone</surname>
                <given-names>KD</given-names>
              </name>
            </person-group>
            <article-title>Atopic dermatitis in children: clinical features, pathophysiology, and treatment.</article-title>
            <source>Immunol Allergy Clin North Am</source>
            <year>2015</year>
            <month>Feb</month>
            <volume>35</volume>
            <issue>1</issue>
            <fpage>161</fpage>
            <page-range>161-83</page-range>
            <pub-id pub-id-type="pmid">25459583</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23843.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wollenberg</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Seba</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Antal</surname>
                <given-names>AS</given-names>
              </name>
            </person-group>
            <article-title>Immunological and molecular targets of atopic dermatitis treatment.</article-title>
            <source>Br J Dermatol</source>
            <year>2014</year>
            <month>Jul</month>
            <volume>170 Suppl 1</volume>
            <fpage>7</fpage>
            <page-range>7-11</page-range>
            <pub-id pub-id-type="pmid">24720588</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23843.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Reed</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Scott</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Bray</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Eczema vaccinatum.</article-title>
            <source>Clin Infect Dis</source>
            <year>2012</year>
            <month>Mar</month>
            <volume>54</volume>
            <issue>6</issue>
            <fpage>832</fpage>
            <page-range>832-40</page-range>
            <pub-id pub-id-type="pmid">22291103</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23843.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sohail</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Khan</surname>
                <given-names>FA</given-names>
              </name>
              <name>
                <surname>Shami</surname>
                <given-names>HB</given-names>
              </name>
              <name>
                <surname>Bashir</surname>
                <given-names>MM</given-names>
              </name>
            </person-group>
            <article-title>Management of eczema herpeticum in a Burn Unit.</article-title>
            <source>J Pak Med Assoc</source>
            <year>2016</year>
            <month>Nov</month>
            <volume>66</volume>
            <issue>11</issue>
            <fpage>1357</fpage>
            <page-range>1357-1361</page-range>
            <pub-id pub-id-type="pmid">27812048</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
